RecruitingPhase 1NCT07143227

A Study of XW003 Injection in Chinese Adolescents With Obesity

A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of XW003 Injection in Chinese Adolescents With Obesity

Sponsor

Hangzhou Sciwind Biosciences Co., Ltd.

Enrollment

48 participants

Start Date

Aug 25, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity Obese Adolescents

Summary

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity

Eligibility

Min Age: 12 YearsMax Age: 18 Years

Inclusion Criteria2

At the time of screening, BMI meets the obesity criteria specified in WS/T586-2018 'screening for overweight and obesity among school-aged children and adolescents', and weight ≥55 kg;
At the time of screening, the decrease of body mass index less than 5% after diet and exercise control alone for at least 12 weeks (as reported by participants or parents or legal guardians);

Exclusion Criteria5

Pre-adolescent participants (Tanner phase I);
Obesity caused by secondary diseases or medications, including: elevated cortisol hormone (e.g. Cushing's syndrome), damage to the pituitary gland and hypothalamus, reduced dosage/discontinuation of weight-loss drugs or monogenic obesity, etc.;
Have used any weight-loss drugs, hypoglycemic drugs, or drugs that may cause significant weight gain within 3 months prior to screening;
Diagnosis with any type of diabetes;
History of acute or chronic pancreatitis, history of gallbladder disease or pancreatic injury

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.